Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for FSK and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for FSK and 80,000+ other tickers.
See exactly how FSK's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for FSK and 80,000+ other tickers.
FS KKR Capital Corp. operates as a Business Development Company (BDC) with a primary investment focus on debt instruments. The firm delivers bespoke financing options specifically tailored for privately held, mid-sized American enterprises. Its investment portfolio predominantly comprises senior secured debt, though it also allocates a smaller portion to subordinated debt issued by these same private U.S. middle-market firms. The company acquires stakes in these loans either by participating in secondary market transactions or by directly providing capital to target companies as primary…
BDCs trade at a steep discount, but the risks the bears talk about most may not be the ones that matter. One overlooked risk, hidden in loans made years ago, is already hurting several well-known names. Some of the most popular BDCs may be more exposed than their results suggest, and the moment of truth is getting closer.
Three BDC lenders are dangling yields above 13%, but a sky-high payout on one of them comes with a trail of red flags that most income investors miss until it is too late to get out whole.
HONG KONG, Oct 23, 2026 - (ACN Newswire) - HighTide Therapeutics, Inc. (2511.HK), an innovative biopharmaceutical company specializing in the development of mul
Two opportunities offer 15%+ dividend yields while trading at approximately 45% discounts to their underlying net asset values. Both appear incredibly cheap, but their underlying fundamentals tell dramatically different stories. I explain why I believe one offers a rare opportunity to lock in enormous income and substantial upside, while the other could be a dangerous value trap.
